

Supplemental Table 2: Antigen and Fc Detection Reagents

Antigen	Source	Fc Detection	Source
H1N1 HA1	Immune Technology IT-003-00110p	a- IgG	Southern Biotech 1030-09
HSV gE	Immune Technology IT-005-005p	a-IgG1	Southern Biotech 9054-09
SARS CoV-2 N	Immune Technology IT-002-033Ep	a-IgG2	Southern Biotech 9070-09
SARS CoV-2 fusion peptide	New England Peptide	a-IgG3	Southern Biotech 9210-09
SARS CoV-2 S1 (for Fc Array)	ACROBiosystems S1N-C52H3-100ug	a-IgG4	Southern Biotech 9200-09
SARS CoV-2 RBD	BEI Resources NR-52366	a-IgA	Southern Biotech 2050-09
SARS CoV-2 S2	Immune Technology IT-002-034p	a-IgA1	Southern Biotech 9130-09
SARS CoV-2 S-2P	Expressed in Expi 293	a-IgA2	Southern Biotech 9140-09
		a-IgM	Southern Biotech 9020-09
		a-IgD	Southern Biotech 9030-09
		Fc α R	Duke Protein Production Facility
		Fc γ R2a	Boesch, et. al, 2014 ¹
		Fc γ R2b	Boesch, et. al, 2014 ¹
		Fc γ R3a	Boesch, et. al, 2014 ¹
		Fc γ R3b	Boesch, et. al, 2014 ¹

¹Boesch AW, Brown EP, Cheng HD, Ofori MO, Normandin E, Nigrovic PA, et al. Highly parallel characterization of IgG Fc binding interactions. *MABs*. 2014;6(4):915-27.